Gut Microbiota-Mediated Elevated Production of Secondary Bile Acids in Chronic Unpredictable Mild Stress

Yuchen Qu†, Cunjin Su†, Qinhong Zhao†, Aiming Shi†, Fenglun Zhao†, Liuxing Tang†, Delai Xu†, Zheng Xiang†, Yang Wang‡, Yueyuan Wang†, Jie Pan†* and Yunli Yu†*

1Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, China, 2College of Pharmaceutical Science, Soochow University, Suzhou, China

A growing body of evidence suggests that gut microbiota could participate in the progression of depression via the microbiota–gut–brain axis. However, the detailed microbial metabolic profile changes in the progression of depression is still not fully elucidated. In this study, a liquid chromatography coupled to mass spectrometry-based untargeted serum high-throughput metabolomics method was first performed to screen for potential biomarkers in a depressive-like state in a chronic unpredictable mild stress (CUMS)-induced mouse model. Our results identified that the bile acid and energy metabolism pathways were significantly affected in CUMS progression. The detailed bile acid profiles were subsequently quantified in the serum, liver, and feces. The results showed that CUMS significantly promoted the deconjugation of conjugated bile acid and secondary bile acid biosynthesis. Furthermore, 16S rRNA gene sequencing revealed that the increased secondary bile acid levels in the feces positively correlated with Ruminococcaceae_UCG-010, Ruminococcus, and Clostridia_UCG-014 abundance. Taken together, our study suggested that changes in family Ruminococcaceae abundance following chronic stress increased biosynthesis of deoxycholic acid (DCA), a unconjugated secondary bile acid in the intestine. Aberrant activation of secondary bile acid biosynthesis pathway thereby increased the hydrophobicity of the bile acid pool, which might, in turn, promoted metabolic disturbances and disease progression in CUMS mice.

Keywords: CUMS, bile acid, gut microbiota, depression, Ruminococcaceae

INTRODUCTION

According to the World Health Organization, an estimated 3.8% of the global population has been affected by depression and the number is still increasing worldwide (World Health Organization, 2021). Modern psychology- and biology-related concepts revealed that depression is not only a common psychological disorder, but also a physical disease complex involving the imbalance of neurotransmitters, injury of neurogenesis, decline of neuroplasticity, and abnormality of neuronal circuitry (Chaudhury et al., 2015; Liu et al., 2017). Recently, with the development of gut microbiota research, a growing body of evidence indicates that the microbiota–gut–brain axis plays an essential role in regulating human behavior and brain function (Foster and McVey Neufeld, 2013; Liang et al., 2018).

An important function of the gut microbiota is participating in bile acid metabolism. Bile acids are the major constituents of the human bile synthesized from cholesterol by perivenous hepatocytes,
playing an important role in dietary fat digestion and absorption (Hofmann., 1999). Most bile acids undergo enterohepatic circulation and microbial biotransformation in the intestinal tract (Chiang and Ferrell, 2018). Cholic and chenodeoxycholic acid are the two primary bile acids synthesized in the liver by a series of enzymatic reactions (Russell., 2003), conjugated with either glycine or taurine, and stored in the gallbladder (He et al., 2003). Bile acids are then secreted into the gastrointestinal tract, where they are subsequently deconjugated, dehydroxylated, and oxidized in the intestinal lumen by gut microbes to generate hydrophobic secondary bile acids: deoxycholic and lithocholic acid (Ridlon et al., 2014).

Recent studies revealed that bile acids might serve as intermediate messengers between the gut and the brain (Monteiro-Cardoso et al., 2021), while the relationship between bile acids and depression have rarely been investigated. In this study, we constructed a chronic unpredictable mild stress (CUMS) model to mimic depression-like symptoms in mice. We sought to explore potential gut microbiota-associated metabolites and the relationship between bile acids and depression progression.

MATERIALS AND METHODS

Chemicals and Reagents

Cholic acid (CA), chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), deoxycholic acid (DCA), lithocholic acid (LCA), taurocholic acid (TCA), taurochenodeoxycholic acid (TCDCA), tauroursodeoxycholic acid (TUDCA), taurodeoxycholic acid (TDCA), taurolithocholic acid (TLCA), glycocholic acid (GCA), glycodeoxycholic acid (GCDCA), glycoursodeoxycholic acid (GUDCA), glycodeoxycholic acid (GDC), and lithocholic acid-2,3,4,4-d5 (internal standard) were all purchased from Sigma-Aldrich (St. Louis, MO, USA). Glycolithocholic acid (GLCA) was purchased from J&K Scientific Ltd. (Shanghai, China). HPLC-grade ammonium formate (≥99%), ammonium acetate, methanol, and acetonitrile were purchased from Merck KGaA (Darmstadt, Germany). HPLC-grade formic acid (99%) was purchased from Anaqua Chemicals Supply (Wilmington, USA).

Animals and CUMS Experiment

Seven-week-old male ICR mice were purchased from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). After their arrival, mice were single-caged and divided into the normal control group and the CUMS model group of 12 animals each randomly based on their body weight and sucrose preference test results. Mice were acclimated for 7 days in a temperature–humidity-controlled (40°–60%) room under a 12-h light/dark cycle (lights on 07:00–19:00) with free access to food and water. During the modeling period, mice were weighed biweekly.

CUMS progression contained a total of 8 different stimulations including: 1) food deprivation for 24 h, 2) water deprivation for 24 h, 3) damp sawdust for 24 h, 4) tail pinching for 2 min, 5) restraint for 1 h, 6) cage tilting at 45° for 24 h, 7) cold swimming for 10 min, and 8) day and night reversal for 24 h. Two or three types of stimulations were delivered daily and randomly to the mice in the model groups for 56 days.

Behavioral Tests and Sample Collection

Depression-related behavioral tests including the sucrose preference test (SPT), forced swim test (FST), and tail suspension test (TST) were performed during the experimental period.

For the SPT, all mice were habituated to 1% sucrose solution during the adaptation cycles. After the adaptation progression, mice were deprived of water and food for 12 h and were provided with free access to two tubes containing 20 ml of sucrose solution (1% w/v) and water respectively for 5 h. The sucrose preference rate was calculated subsequently using the following formula: sucrose preference = volume of sucrose consumed/total volume (water and sucrose) consumed × 100%. We performed the SPT on day 57 to evaluate the modeling effect.

We conducted the forced swim and tail suspension tests on days 58 and 59, respectively. During the forced swim test, the mice were individually placed into glass cylinders (height of 40 cm, diameter of 18 cm) containing 25°C water at a depth of 15 cm for 10 min. Immobility time was measured of last 4 min was recorded to estimate the symptom of depression. During the tail suspension test, mice were individually suspended by their tails for 6 min using a small piece of tape on the shelf, placed at the height of 60 cm above the floor. The duration of immobility during the final 4 min was recorded to measure depressive status.

On day 60, serum and feces were collected after 12 h of fasting. Livers and intestinal contents were removed immediately after the mice had been sacrificed. All samples were stored in a freezer at ~80°C for further processing.

Untargeted Metabolomic Analysis

Serum samples were thawed on ice and 400 µl of methanol was subsequently added into 100 µl of serum sample in an EP tube. The mixture was vortexed for 1 min and centrifuged at 15,000 g for 10 min at 4°C. The supernatant was then transferred into another EP tube and evaporated to dry with an Eppendorf Vacufuge Concentrator 5305. The residue was resuspended in 150 µl of 80% methanol and filtered through a 0.22-µm nylon syringe filter. For all samples, equal volumes of solutions were mixed into quality controlled samples to evaluate instrument analysis stability and repeatability.

The separation of the target compounds was performed on a Waters ACQUITY UPLC HSS T3 (2.1 mm × 150 mm, 1.8 µm) liquid chromatography column at 40°C with a ACQUITY UPLC CS C18 VanGuard Pre-column (2.1 mm × 5 mm, 1.7 µm) using a Dionex Ultimate 3000 UPLC system. The mobile phase contained 0.1% aqueous formic acid and 0.1% formic acid in acetonitrile in positive ion mode and 5 mM ammonium formate aqueous buffer and acetonitrile in negative ion mode. The mobile phase flow rate was 0.25 ml/min and the injection volume was 5 µl, both in the positive and negative ion modes. Supplementary Table S1 presents the detailed gradient elution conditions. The Q
Data Processing and Metabolite Identification
Metabolomics analysis was carried out by BioNovoGene (Suzhou, China). After the raw data files were converted into an mzXML format by the ProteoWizard software (v3.0.8789), the freely available XCMS software was used to perform peak identification, filtration, alignment, and integration. The three-dimensional data matrix, including retention time, mass to charge ratio, and intensity, was converted into a table for further process analysis. In order to compare the data of different magnitudes, the peak area of the data was batch-normalized before multivariate statistical analysis. The data were then uploaded into SIMCA-P 13.0 to perform principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). Autoscaling was used in all the models to achieve more scientific, reliable, and intuitive results. The variable importance in the project values (VIP) obtained from the OPLS-DA model and p-value from Student’s t-test were used to select the potential metabolites in the study. Metabolites with VIP > 1 and p-value < 0.05 were considered statistically significant. These potential metabolites were subsequently subjected to pathway analysis performed through MetaboAnalyst 5.0 (https://www.metaboanalyst.ca/).

Bile Acid Quantification in the Serum, Feces, and Liver
The bile acid profiles in the serum, feces, and liver were quantified using our previously validated UPLC-Q/Orbitrap-HRMS methods. Briefly, the bile acids in the feces and liver were extracted with 5 vol of deionized water by Qiagen TissueLyserII. For the feces samples, 200 µL of acetonitrile and 10 µL of 14% ammonia solution were added into 100 µL of fecal suspensions spiked with internal standard. For the serum and liver homogenates, 400 µL of acetonitrile was added into 100 µL of sample spiked with internal standard. For the serum and corresponding to 0.22-µm nylon syringe filter. All blank matrix used for the calibration standard configurations and quality control samples were prepared using the activated carbon adsorption method.

The separation of the target compounds was performed on the same instrument and column as described above. The mobile phase flow rate and injection volume were 0.2 ml/min and 5 µL, respectively, with 10 mM ammonium formate aqueous buffer (A) and acetonitrile (B). The optimized gradient elution (0–7 min, 35–60% B; 7–8.5 min, 60–95% B; 8.5–12 min, 95% B; 12–12.3 min, 95%–35% B; 12.3–16 min, 35% B) was performed to separate the different bile acid components. Acquisition was performed in negative selective ion monitoring mode. All MS spectra were acquired and analyzed using the Xcalibur 4.0 software.

16S rRNA Sequencing Analysis
Total genomic DNA from the intestinal contents (5 samples from each of the control and model group) was extracted using the HiPure Stool DNA Kit (Megan, Guangzhou, China) according to the manufacturer’s protocols. The DNA concentration was measured using the Equalbit dsDNA HS Assay Kit (Novizan, Nanjing China). The NGS library preparation and Illumina sequencing was performed by GENEWIZ, Inc. (Suzhou, China). Approximately 20–30 ng of DNA was used to generate amplicons. The V3 and V4 hypervariable microbial 16S rDNA regions were amplified by PCR using a panel of proprietary primers designed by GENEWIZ. A linker with an index was then added to the end of the PCR product of 16S rDNA by PCR for NGS sequencing. The obtained sequencing library was subsequently purified with magnetic beads, followed by library quality control checks using a microplate reader and agarose gel electrophoresis. The library was then quantified to 10 nM and PE250/FE300 paired-end sequencing was performed using an Illumina MiSeq instrument (Illumina, San Diego, CA, USA).

Next, the forward and reverse reads were joined in pairs, followed by filtering the sequences containing N in the splicing results and retaining the sequences with a length beyond 200 bp. The obtained longer sequences were used to perform sequence clustering using VSEARCH (1.9.6) (sequence similarity was set to 97%) against the Silva_138 16SrRNA database (http://www.arb-silva.de/). The Ribosomal Database Program classifier was used to assign taxonomic categories to predict the community composition at the genus levels. Sequence data associated with this project have been deposited in the NCBI database (Accession Number: PRJNA796629).

Statistical Analysis
All statistical analyses were performed using the GraphPad Prism 9.0 software. A two-tailed t-test was performed to compare between the groups and statistically significant differences were labeled with one, two, three, or four asterisks corresponding to p < 0.05, p < 0.01, or p < 0.001, respectively. Correlations between the gut microbiotic abundance and bile acid profiles were estimated using Pearson’s correlation analysis.

RESULTS
Body Weight Changes and Depression-Like Behavior Validation
The body weight of the animals was measured before and during the treatment period. The mice in the model group gained less...
weight than control group at the end of the CUMS progression (Figures 1A–D). In addition, significant CUMS effects were present in the case of the sucrose consumption in SPT, immobility time in both FST and TST compared with the control group. The results demonstrated that a CUMS mouse model was successfully created.

Differential Metabolite Screening in Untargeted Metabolomic Analysis

To investigate the impact of chronic stress upon the metabolomic profiling, untargeted metabolomic analysis was performed to analyze the metabolite composition in the serum of mice. The obvious separation trend from the PCA (Supplementary Figure S1) and the OPLS-DA (Figures 2A,B) score plot indicated metabolic differences between the groups. Our OPLS-DA permutation test showed that the model we established was not over-fitting (Figures 2C,D).

In order to screen out potential metabolites, we used the VIP value of the OPLS-DA model beyond 1.0 and the p-value of the two-tailed unpaired Student’s t-test results less than 0.05 as a threshold to distinguish the metabolites from the model and control groups. A total of 74 metabolites were significantly changed during the CUMS progression. Table 1 shows the detailed information of these metabolites. The affected pathways mainly involved amino acid, sugar, nucleotide metabolism, unsaturated fatty acid biosynthesis and metabolism, vitamin synthesis and absorption, and bile acid metabolism. Supplementary Figure S2A and Supplementary Table S2 show the bubble chart of the KEGG pathway analysis and the detailed information of the pathway analysis, respectively. We found that the two main primary bile acid (chenodeoxycholic acid and taurocholic acid) levels were significantly altered in the model group, indicating abnormalities in bile acid synthesis or metabolism.

Effect of CUMS on Bile Acid Composition in the Serum

To further examine the bile acid metabolism disrupted by CUMS progression, we quantified the detailed bile acid profiles in the serum using our previously established method (Supplementary Figure S3 shows the chromatographic separation of the different components). CUMS significantly increased the level of three free bile acids, UDCA (345% ↑, p = 0.0314), CDCA (220% ↑, p = 0.0152), and DCA (197% ↑, p = 0.0009), whereas it significantly reduced the level of taurine-conjugated primary bile acid TCA (56% ↓, p = 0.0452) (Figure 3A). The taurine-conjugated-to-free bile acid ratios in the model group were significantly lower than those in the control group (Figure 4A). In addition, the hydrophobicity index (HI) of the circulating bile acid pool was calculated as described previously (Heuman, 1989). We observed that the HI in the model group was significantly higher than that in the control group (Figure 4B).

Effect of CUMS on Bile Acid Composition in the Liver and Feces

Next, we quantified the bile acid profiles in the liver and feces to evaluate the effect of CUMS on bile acid biosynthesis and
metabolism. CUMS significantly increased the secondary bile acid levels in the feces and liver (Figures 3B,C). In particular, the model group liver samples showed increased DCA (148%↑, p = 0.0198), TDCA (166%↑, p = 0.0222), and TLCA (137%↑, p = 0.0028) levels and the model group feces samples showed increased DCA (117%↑, p = 0.0343), TDCA (304%↑, p = 0.0034), and GDCA (306%↑, p = 0.0061) levels.

Since DCA is the microbial metabolic product of TCA, we calculated the relative TCA-to-DCA ratios in the control and model groups to indirectly address the effects of the gut microbiota. The TCA/DCA ratio significantly decreased in the serum and liver of model group (Figure 5). Our results indicated that CUMS markedly promoted intestinal secondary bile acid formation.

**Association Between the Gut Microbiotic Abundance and Bile Acid Profiles**

We identified a total of 65 bacteria in the intestinal tract from the intestinal content samples at the genus level and summarized the heatmap of the relative abundance in the top 30 genera (Figure 6A). Pearson’s correlation analysis (Figure 6B) indicated that increased secondary bile acid levels in the feces significantly and positively correlated with three members of the phylum Firmicutes: Ruminococcaceae_UGC-010, Ruminococcus, and Clostridia_UGC-014. This result suggested that changes in the secondary bile acid formation might be associated with altered gut microbiota composition in the intestine.

**DISCUSSION**

In this study, we constructed a CUMS model to mimic depressive behavior in ICR mice with adverse stress in order to explore how depression could affect metabolism. These mice were weighed every 2 weeks and significant body weight gain reduction could be observed in model groups compared to the control. The SPT results showed that 8 weeks of CUMS significantly reduced sucrose solution consumption. The tail suspension and the forced swim tests are the most direct and effective methods to evaluate depressive behaviors in animals (Can et al., 2012; Slattery and Cryan, 2012). The immobility time of the model group during both the TST and FST significantly increased compared with that of the control. These behavioral results consistently supported that we successfully developed a CUMS model in ICR mice.

Metabolomics is an important component of systems biology, which can directly reflect the state of organisms (Fiehn, 2002). Our PCA and OPLS-DA score plots showed significant separation of the different groups, indicating that obvious metabolic differences occurred during CUMS progression. However, the pathway enrichment map revealed that the most
impacted pathways mainly involved the energy metabolism, extensively studied in the field of depression. Upon further analysis of these metabolites, two primary bile acids were significantly altered in the model group, indicating that CUMS progression might cause bile acid metabolism disorder. In order to clarify how CUMS could affect bile acid metabolism, we quantified the detailed bile acid profiles in the serum, liver, and feces by UPLC-Q/Orbitrap-HRMS.

Bile acids are a group of amphipathic steroid molecules generated by hepatic and bacterial enzymes, playing an important role in regulating metabolism and immune response (Hofmann, 1999; Jia et al., 2018). Recent evidence suggests that bile acids might also play a role in mediating microbiota–gut–brain axis functions by interacting with their receptors in the brain (Monteiro-Cardoso et al., 2021). Specifically, altered bile acid profiles were associated with cognitive impairment in Alzheimer’s and Parkinson’s disease (MahmoudianDehkordi et al., 2019; Baloni et al., 2020; Li et al., 2021). Bile acid administration, particularly that of TUDCA and UDCA, contributed to neurologic symptom improvements in animal models of Alzheimer’s, Parkinson’s, and Huntington disease (Keene et al., 2002; Lo et al., 2013; Cuevas et al., 2020). However, bile acid metabolism in depression has rarely been described. There is an urgent need to elucidate how chronic stress affects bile acid profiles.

It is well-known that a variety of bile acid subtypes are present within the circulating bile acid pool (Yang et al., 2017). It has been difficult to appreciate the exact contribution of each bile acid to the whole body since each bile acid has the ability to bind and modulate the activity of transmembrane and nuclear receptors (Kundu et al., 2015). Different bile acid subtypes exhibit varying degrees of hydrophobicity, determined by factors such as state of ionization and hydroxyl group number, position, and orientation (Heuman, 1989). Circulating bile acid profile HI can be used to evaluate how bile acid profile alterations impact biological, physical, and chemical properties are related to the ability of compounds to bind to or dissolve in hydrophobic domains such as membrane, micelles, or certain receptor sites, HI can be used to evaluate how bile acid profile alterations impact

**TABLE 1 | Identification of different metabolites.**

| Metabolites                  | KEGG ID   | Model/control | Metabolites                  | KEGG ID   | Model/control |
|------------------------------|-----------|---------------|------------------------------|-----------|---------------|
| S-Adenosylhomocysteine       | C00021    | ↓             | N-Acetylserotonin            | C00978    | ↑             |
| Pyruvic acid                 | C00022    | ↓             | N-Acetyl-L-aspartic acid      | C01042    | ↓             |
| L-Glutamic acid              | C00025    | ↑             | 4-Hydroxyphenylpyruvic acid  | C01179    | ↓             |
| Oxoglutaric acid             | C00026    | ↑             | Anserine                     | C01262    | ↑             |
| L-Aspartic acid              | C00049    | ↑             | L-Neolec acid                | C01595    | ↑             |
| L-Arginine                   | C00062    | ↑             | L-Kynurenic acid             | C01717    | ↑             |
| L-Serine                     | C00065    | ↑             | Pyroglutamic acid            | C01879    | ↑             |
| d-Fructose                   | C00095    | ↑             | 5-Methylcyotosine            | C02376    | ↑             |
| 2-Ketobutyric acid           | C00109    | ↓             | Xanthurenic acid             | C02470    | ↑             |
| Fumaric acid                 | C00122    | ↓             | Chenodeoxycholic acid        | C02528    | ↑             |
| Adenine                      | C00147    | ↑             | Uredopropionic acid          | C02642    | ↑             |
| L-Proline                    | C00148    | ↑             | N-Formyl-L-methionine         | C03145    | ↓             |
| 5-Methylthiadenosine         | C00170    | ↑             | 3-Hydroxykynurene             | C03227    | ↓             |
| L-Lactic acid                | C00186    | ↑             | 2-Oxogargin                   | C03771    | ↓             |
| 3-Phosphoglyceric acid       | C00197    | ↑             | 2-Dehydro-3-deoxy-L-rhamnonate| C03979   | ↑             |
| Thymidine                    | C00214    | ↑             | L-Octopine                   | C04137    | ↑             |
| Butyric acid                 | C00246    | ↑             | 13-L-Hydroperoxylineoleic acid| C04717  | ↑             |
| L-Sorbose                    | C00247    | ↓             | Taurocholic acid             | C05122    | ↓             |
| Nicotinic acid               | C00253    | ↑             | Phenyllethylamine             | C05332    | ↑             |
| Riboflavin                   | C00255    | ↑             | beta-c-Fructose 6-phosphate   | C05345    | ↓             |
| Gluconic acid                | C00257    | ↑             | 5(S)-HpETE                   | C05356    | ↓             |
| Uridine                      | C00299    | ↑             | Ergothioneine                | C05570    | ↓             |
| Retinal                      | C00376    | ↑             | 3,4-Dihydroxyandelic acid    | C05580    | ↓             |
| Carnosine                    | C00386    | ↑             | Metanephrine                 | C05588    | ↓             |
| cis-Aconitic acid            | C00417    | ↑             | 5-Hydroxyindoleacetic acid   | C05635    | ↓             |
| Prostaglandin H2             | C00427    | ↓             | Prostaglandin G2             | C05956    | ↓             |
| Saccharopine                 | C00449    | ↓             | Prostaglandin J2             | C05967    | ↓             |
| Nicotinamide ribotide        | C00455    | ↓             | 6-Keto-prostaglandin F1a     | C05961    | ↓             |
| Retinol                      | C00473    | ↓             | Saldroside                   | C06046    | ↓             |
| Cytidine                     | C00475    | ↑             | Skatole                      | C08313    | ↑             |
| Glutaric acid                | C00489    | ↓             | 13S-hydroxyoctadecadienoic acid| C14762 | ↑             |
| L-Fucose                     | C00507    | ↓             | 12-KETE                      | C14807    | ↑             |
| L-Arabiononate               | C00545    | ↑             | 9(S)-HPODE                   | C14827    | ↓             |
| 5-Dehydro-4-deoxy-o-glucarate| C00679    | ↓             | 12,13-DHOME                  | C14829    | ↑             |
| Betaine                      | C00719    | ↑             | Stearidonic acid             | C16300    | ↑             |
| Glucaric acid                | C00818    | ↑             | Traumatic Acid               | C16308    | ↑             |
| Indole-3-acetic acid         | C00954    | ↑             | (2E,4Z,7Z,8E)-Cohlenenic acid| C16320   | ↑             |

Different metabolites were identified from the OPLS-DA, model based on VIP > 1 and p < 0.05. ↑ indicates upregulated metabolites. ↓ indicates downregulated metabolites.
body function (Haeusler et al., 2013). Therefore, we calculated the circulating bile acid pool HI in the serum and observed remarkably raised bile acid pool HI in the model group.

Apart from HI, the conjugated/free and primary/secondary form ratios are additional characteristics of host bile acid homeostasis. We observed that the conjugated-to-free form...
ratios in the serum significantly reduced in the model group. In addition, secondary bile acid levels, especially that of DCA, markedly increased in the model group. Since DCA is the metabolic product of TCA, we further compared the TCA/DCA ratio in control and model groups. Consequently, the TCA/DCA ratios in the serum and liver significantly decreased in the model group. These results indicated that the secondary bile acid biosynthesis pathway had been activated during CUMS progression, potentially explaining the increased HI in the serum.

Mitochondrial dysfunction and oxidative stress are supposed to be involved in the pathophysiology of depression (Bansal and Kuhad, 2016; Bhatt et al., 2020). Indeed, hydrophobic bile acid species show cytotoxicity due to their detergent action and oxidation effects (Perez and Briz, 2009), whereas hydrophilic bile acids, such as TUDCA mentioned above, exert strong cytoprotective effects by mitochondrial membrane stabilization (Castro et al., 2004). Previous studies demonstrated that multiple bile acids could penetrate the blood-brain barrier, although the involved mechanisms have not yet been fully understood (Mertens et al., 2017). Notably, free bile acids could diffuse across phospholipid bilayers and their brain concentrations correlate with their serum concentrations (Kamp et al., 1993; Higashi et al., 2017). Since chronic stress can disrupt brain homeostasis and increase the blood-brain barrier permeability (Lee et al., 2018), free bile acids might penetrate more easily the blood-brain barrier in the depressive state. In particular, increased DCA level can induce apoptosis and DNA damage (Washo-Stultz et al., 2002; Fu et al., 2019), potentially exacerbating neuroinflammation and oxidative stress contributing to the progression of depression pathology. In our analyses, with CUMS progression, the increased free bile acid levels in serum might have contributed to bile acid composition changes in the brain. This is of particular concern given that the increased DCA level might affect brain physiology.

In addition to direct effects on the central nervous system function, bile acids might also be involved in the metabolic disorders during CUMS progression by regulating receptor such as FXR (farnesoid X receptor) and TGR5 (Takeda G protein-coupled receptor 5). FXR mainly functions as a bile acid sensor in the bile acid regulation feedback and its most potent ligand is CDCA (Liu et al., 2020). Furthermore, current evidence suggests FXR also participates in bile acid-mediated energy metabolism. FXR deficient mice exhibited impaired glucose tolerance and reduced insulin sensitivity (Ma et al., 2006). FXR activation in the intestine promotes the release of fibroblast growth factor (FGF) 15/19, proved to serve as important regulators to improve glucose metabolism in the gut–brain axis by binding FGF receptors in the hypothalamus (Liu et al., 2018). TGR5 is a G protein-coupled bile acid receptor that mediates glucose homeostasis by producing glucagon-like peptide 1. TGR5 is mainly activated by secondary bile acids, including LCA, DCA, and TLCA in vivo (Liu et al., 2020). Our serum untargeted metabolomics results revealed multiple...
Carbohydrate metabolism pathways were significantly enriched, which might be associated with the bile acid metabolism disorders in CUMS progression. Beyond that, the latest research indicated that bile acid receptors in the brain were also directly involved in the pathogenesis of depression. The protein and mRNA expressions of FXR in hippocampus were significantly increased in CUMS induced depressive rats (Chen et al., 2018), and FXR overexpression aggravated depression-like behaviors by inhibiting brain-derived neurotrophic factor signaling in the hippocampus (Hu et al., 2020). Multiple types of chronic stressors significantly reduced TGR5 expression in hippocampal CA3 pyramidal neurons of C57BL/6j mice, whereas genetic overexpression of TGR5 or intra-CA3 infusion of the TGR5 agonist was able to reverse depressive-like behaviors by CA3 pyramidal neurons activation (Wang et al., 2021). In our present study, hepatic FXR and TGR5 expressions were not significantly altered in CUMS progression (data not shown), indicating that CUMS might exert different effects on bile acid reporters in different tissues. Bile acid profile and FXR and TGR5 expression in the brain will be the focus of our further investigation to elucidate the regulation of the pathogenesis of depression.

It is known that gut microbiota plays an essential role in the development of depression (Sanada et al., 2020), recognized as a possible reason for depression causing bile acid metabolism disorder. The deconjugation of conjugated bile acids in vivo is mainly catalyzed by bile salt hydrolase, widely expressed by multiple common commensal genera, especially Bacteroides, Lactobacillus, and Clostridium (Song et al., 2019; Adhikari et al., 2020). Another microbial bile salt transformation in vivo is to form secondary bile acids from primary bile acids by 7α-dehydroxylation. Currently known bacteria expressing 7α-dehydroxylase are all of the Ruminococcaceae and Lachnospiraceae families (Stellwag and Hylemon, 1978; Takamine and Imamura, 1995). As shown in Supplementary Figure S4, two genera of family Ruminococcaceae, Ruminococcaceae_UCG-010 and Ruminococcus, were significantly positively correlated with the secondary bile acid levels in feces, which might partly explain the increased secondary bile acids in model group.

Accumulating number of studies demonstrated that Ruminococcaceae might affect brain function and behavior. Tran et al. found that the abundance of Ruminococcaceae were correlated with the apolipoprotein E genotype in healthy participants (Tran et al., 2019). Depletion of Ruminococcaceae was proved to be closely associated with reduced cognitive functions Alzheimer’s disease (Vogt et al., 2017; D’Amato et al., 2020). At the genus level, the genus Ruminococcus is well known as butyric acid-producing bacteria which plays an important role in intestinal inflammation (Louis and Flint, 2017; Henke et al., 2019) (elevated butyric acid level was also observed in model group from the serum untargeted metabolomics data). Recent research revealed the importance of decreasing Ruminococcus for duloxetine to reduce depressive behavior (Lukić et al., 2019), indirectly indicating that Ruminococcus involved in the occurrence and progression of depression. Our current results further complement these previous study findings demonstrating the critical role of Ruminococcaceae by regulating bile acid metabolism in microbiota–gut–brain axis.

CONCLUSION

Our findings provide a novel perspective to elucidate the microbiota–gut–brain crosstalk in depression. Chronic stress-induced gut microbiota modifications, especially changes in relative abundance of family Ruminococcaceae, contributed to increased biosynthesis of secondary bile acid DCA in the intestine. This gut microbiota-mediated bile acid metabolic imbalance subsequently increased the hydrophobicity of the bile acid pool, which might in turn promote the energy metabolism disorder and pathophysiological changes in CUMS progression.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: NCBI database (BioProject: PRJNA796629, BioSample:SAMN24905304).

ETHICS STATEMENT

The animal study was reviewed and approved by Ethics Committee of Soochow University.

AUTHOR CONTRIBUTIONS

YQ and CS: designed the study and wrote the manuscript. YQ, QZ, FZ, LT, DX, ZX, and YW: performed the experiments. YQ, AS, and YW analyzed metabolomic data. JP and YY supervised the project and revised the manuscript.

FUNDING

This work was supported by Natural Science Foundation of China (82173879), Jiangsu Pharmaceutical Association (Q202019, H202122), Lift Project for Discipline Construction of The Second Affiliated Hospital of Soochow University (XKTJ-XK202010), the Second Affiliate Hospital of Soochow University Talent Promotion Project (XKTJ-RC202013, XKTJ-RC202014), Suzhou Science Foundation (SYS2019058) Suzhou Health Talent Project (GWW2020025), Suzhou Science and Technology Development Plan (SS2019042).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.837543/full#supplementary-material
